Investigation Into Sensus Healthcare, Inc.
Pomerantz LLP is actively investigating potential claims on behalf of investors associated with Sensus Healthcare, Inc. (NASDAQ: SRTS). This investigation aims to determine if the company or any of its executives engaged in unlawful business practices or securities fraud.
Financial Performance Review
In a recent report for the second quarter of 2025, Sensus Healthcare disclosed its financial results, which showed a GAAP earnings-per-share figure of -$0.06. This result fell short of market expectations by $0.09. Additionally, the company reported a revenue of $7.3 million, which marked a 20.7% decline compared to the previous year, also missing estimates by $2 million.
Reasons Behind Revenue Decline
Sensus attributed the decline in revenue primarily to a reduced number of units sold to a significant customer. However, it did note some growth in recurring revenue from Fair Deal Agreements, which helped partially offset the lower sales from unit sales.
Market Reaction
Following the announcement of these disappointing results, Sensus's stock price plummeted by $1.89 per share, a 35.32% drop, concluding the trading day at $3.46 per share. This significant decrease reflects investor sentiment and concerns regarding the company's performance.
Pomerantz LLP's Commitment to Investors
Pomerantz LLP operates with a strong reputation in the legal sector, particularly in corporate, securities, and antitrust class action litigation. Established over 85 years ago by the late Abraham L. Pomerantz, the firm has been a pioneer in advocating for victims of securities fraud and corporate misconduct.
Track Record of Success
The firm has a notable history of recovering multimillion-dollar damages for its clients and remains dedicated to ensuring justice for those affected by fraudulent practices. Pomerantz's commitment to protecting investor rights is unwavering, as they strive to hold companies accountable for their actions.
How Investors Can Reach Out
For any investors who are concerned about their potential investment in Sensus Healthcare, Pomerantz LLP encourages them to reach out. Contact information for Danielle Peyton is available for those wishing to seek guidance or participate in this investigation.
Contact Information
Interested shareholders can contact Danielle Peyton at the firm for assistance and inquiries. Pomerantz LLP remains vigilant in addressing any wrongdoing in the financial sector and welcomes those who believe they have been affected to join their efforts.
Frequently Asked Questions
What is the investigation about?
The investigation by Pomerantz LLP focuses on potential securities fraud involving Sensus Healthcare and its executives.
What were Sensus Healthcare's recent financial results?
The company reported a second quarter earnings per share of -$0.06 and revenue of $7.3 million, missing estimates.
How did the market react to these findings?
Following the financial announcement, Sensus's stock price fell by 35.32%, indicating investor concern.
What should affected investors do?
Affected investors are encouraged to contact Pomerantz LLP for potential participation in the investigation.
Who can I contact for more information?
Investors can reach out to Danielle Peyton at Pomerantz LLP for assistance and further details regarding the investigation.
